Literature DB >> 22915192

Lack of MGMT promoter hypermethylation in hemangiopericytomas of the central nervous system.

Benjamin Brokinkel, Susanne Peetz-Dienhart, Kathy Keyvani, Walter Stummer, Werner Paulus, Martin Hasselblatt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22915192     DOI： 10.1007/s11060-012-0967-4

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  3 in total

1.  MGMT promoter methylation status in anaplastic meningiomas.

Authors:  Benjamin Brokinkel; Bernhard R Fischer; Susanne Peetz-Dienhart; Heinrich Ebel; Abolghassem Sepehrnia; Burckhard Rama; Friedrich K Albert; Walter Stummer; Werner Paulus; Martin Hasselblatt
Journal:  J Neurooncol       Date:  2010-05-07       Impact factor: 4.130

2.  Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor.

Authors:  Min S Park; Shreyaskumar R Patel; Joseph A Ludwig; Jonathan C Trent; Charles A Conrad; Alexander J Lazar; Wei-Lien Wang; Piyaporn Boonsirikamchai; Haesun Choi; Xuemei Wang; Robert S Benjamin; Dejka M Araujo
Journal:  Cancer       Date:  2011-04-08       Impact factor: 6.860

3.  The status of MGMT protein expression is a prognostic factor for meningeal hemangiopericytoma: a clinicopathologic and immunohistochemical study of 12 cases at a single institution.

Authors:  I-Wei Chang; Jui-Wei Lin; You-Ting Wu
Journal:  J Neurooncol       Date:  2011-06-11       Impact factor: 4.130
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.